Importantly, combined CsA and bevacizumab produced a larger inhibition of MMP-3 and MMP-13 expression and of pterygium fibroblast migration, as compared to treatment with bevacizumab or CsA alone (Figs 7 and 8). Here, MMP3 is linked to pterygium.